Access the full text.
Sign up today, get DeepDyve free for 14 days.
(1982)
Chromatographie industrielle, production et qualitt de l'albumine humaine d'origine placentaire
R. Christie (1987)
SAFETY OF ALBUMIN PREPARATIONS MANUFACTURED FROM PLASMA NOT TESTED FOR HIV ANTIBODYThe Lancet, 330
C. Horsburgh, S. Holmberg (1988)
The global distribution of human immunodeficiency virus type 2 (HIV‐2) infectionTransfusion, 28
S. Feinstone, K. Mihalik, '. Tomoteru, Kamimura, J. Harvey, Alter, W. London (1983)
Inactivation of hepatitis B virus and non-A, non-B hepatitis by chloroformInfection and Immunity, 41
G. Mitra, M. Wong, MM Mozen, J. Mcdougal, J. Levy (1986)
Elimination of infectious retroviruses during preparation of immunoglobulinsTransfusion, 26
(1985)
Inactivation of HTLV - IIULAV during plasma fractionation ( letter )
(1956)
The preparation of y = globulin from placental blood by ethanol fractionation
M. Wells, A. Wittek, J. Epstein, C. Marcus-Sekura, S. Daniel, D. Tankersley, M. Preston, G. Quinnan, (1986)
Inactivation and partition of human T‐cell lymphotrophic virus, type III, during ethanol fractionation of plasmaTransfusion, 26
M. Rey, Bruno Spire, Dominique Dormont, F. Barré-Sinoussi, Luc Montagnier, J. Chermann (1984)
Characterization of the RNA dependent DNA polymerase of a new human T-lymphotropic retrovirus (lymphadenopathy associated virus).Biochemical and biophysical research communications, 121 1
F. Barré-Sinoussi, J. Chermann, F. Rey, M. Nugeyre, S. Chamaret, J. Gruest, C. Dauguet, C. Axler-Blin, F. Vézinet-Brun, C. Rouzioux, W. Rozenbaum, L. Montagnier (1983)
Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS).Science, 220 4599
(1982)
Purification de I'albumine humaine par chromatographie
(1986)
Inactivation of human immunodeficiency virus during processing of plasma products
L. Resnick, K. Veren, S. Salahuddin, S. Tondreau, P. Markham (1986)
Stability and inactivation of HTLV-III/LAV under clinical and laboratory environments.JAMA, 255 14
I. Miyoshi, H. Taguchi, I. Kubonishi, S. Yoshimoto, Y. Ohtsuki, Y. Shiraishi, T. Akagi (1982)
Type C Virus-Producing Cell Lines Derived from Adult T Cell Leukemia
F. Clavel, D. Guétard, F. Brun-vezinet, S. Chamaret, M. Rey, M. Santos-Ferreira, A. Laurent, C. Dauguet, C. Katlama, C. Rouzioux (1986)
Isolation of a new human retrovirus from West African patients with AIDS.Science, 233 4761
(2010)
Rapid communications
J. Pla, J. Liautaud, A. Debrus, P. Gattel, R. Plan, L. Peyron (1974)
[Preparation of human albumin from hemolysed blood from frozen placental extracts. II. Elimination of certain impurities during purification].Developments in biological standardization, 27
Bossell Bossell (1986)
Safety of therapeutic immune globulin preparations with respect to transmission of human T‐lymphotropic virus type III/lymphadenopathy‐associated virus infectionMorbid Mortal Weekly Report, 35
J., S. McDougal, L. Martin, S. Cort, M. Mozen, C. Heldebrant, B. Evatt (1985)
Thermal inactivation of the acquired immunodeficiency syndrome virus, human T lymphotropic virus-III/lymphadenopathy-associated virus, with special reference to antihemophilic factor.The Journal of clinical investigation, 76 2
H. Taylor, F. Bloom, K. Mccall, L. Hyndman (1956)
An Improved Procedure for the Preparation of Human Serum Albumin from Placental ExtractsJournal of the American Chemical Society, 78
Harada Harada, Koyanagi Koyanagi, Yamamoto Yamamoto (1985)
Infection of HTLV‐III/LAV in HTLV‐I‐carrying MT‐2 and MT‐4 and application in a plaque assayScience, 229
Bruno Spire, F. Barré-Sinoussi, D. Dormont, L. Montagnier, J. Chermann (1985)
INACTIVATION OF LYMPHADENOPATHY-ASSOCIATED VIRUS BY HEAT, GAMMA RAYS, AND ULTRAVIOLET LIGHTThe Lancet, 325
L. Martin, J. Mcdougal, S. Loskoski (1985)
Disinfection and inactivation of the human T lymphotropic virus type III/Lymphadenopathy-associated virus.The Journal of infectious diseases, 152 2
Bruno Spire, L. Montagnier, F. Barré-Sinoussi, J. Chermann (1984)
INACTIVATION OF LYMPHADENOPATHY ASSOCIATED VIRUS BY CHEMICAL DISINFECTANTSThe Lancet, 324
Infection of HTLV - IIVLAV I 2 1 : 126 - 33 . 22 . 23 . 24 . 25 . 26 . 27 . in HTLV - I - carrying MT2 and MT - 4 and application in a plaque assay
S. Barandun, V. Castel, M. Makula, A. Morell, R. Plan, F. Skvaril (1975)
Clinical tolerance and catabolism of plasmin-treated gamma-globulin for intravenous application.Vox sanguinis, 28 3
J. Liautaud, J. Pla, A. Debrus, P. Gattel, R. Plan, L. Peyron (1974)
[Preparation of human albumin from hemolysed blood from frozen placental extracts. I. Technique for preparation and quality of the product].Developments in biological standardization, 27
Quinnan Quinnan, Wells Wells, Wittek Wittek (1986)
Inactivation of human T‐cell lymphotropic virus, type III by heat, chemicals, and irradiationTransfusion, 26
(1983)
Case for concluding that heat - treated , licensed anti - haemophilic factor is free from HTLV - 111 ( letter )
J. Bossell (1986)
Safety of Therapeutic Immune Globulin Preparations with Respect to Transmission of Human T-Lymphotropic Virus Type III/Lymphadenopathy-Associated Virus InfectionClinical Pediatrics, 25
A laboratory study was undertaken to verify the elimination and/or inactivation of the human immunodeficiency viruses HIV‐1 and HIV‐2 during the manufacture of placental albumin and the gammaglobulins Gamma 16 and Veinoglobuline. Nine steps of the process were selected for study. Samples of current production batches were taken at these different stages and a known quantity of virus was added. Each sample was then processed according to the production schedule for the corresponding step, and the residual viral activity was measured. In eight of nine steps, a complete viral clearance was achieved. Estimation of the cumulative infectivity reduction due to these nine steps is in the following range: >12 to 16 log10 HIV‐1 and >17 to 19 log10 HIV‐2 for Gamma 16, >9 to 13 log10 HIV‐1 and >13 to 15 log10 HIV‐2 for Veinoglobuline, and >19.7 log10 HIV‐1 and >24 log10 HIV‐2 for albumin. As many other purification steps were not included in this study, the real infectivity reduction capacity for the whole process probably exceeds these values. Nevertheless, the levels of inactivation measured clearly document a rigorous fractionation process that has a high assurance of killing or eliminating all contaminating virus. TRANSFUSION 1989;29:629–634.
Transfusion – Wiley
Published: Sep 1, 1989
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.